Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients. / Viller Tuxen, Ida; Barlebo Ahlborn, Lise; Mau-Soerensen, Morten; Staal Rohrberg, Kristoffer; Cilius Nielsen, Finn; Oestrup, Olga; Westmose Yde, Christina; Richter Vogelius, Ivan; Lassen, Ulrik.
I: British Journal of Cancer, Bind 121, Nr. 2, 2019, s. 125-130.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients
AU - Viller Tuxen, Ida
AU - Barlebo Ahlborn, Lise
AU - Mau-Soerensen, Morten
AU - Staal Rohrberg, Kristoffer
AU - Cilius Nielsen, Finn
AU - Oestrup, Olga
AU - Westmose Yde, Christina
AU - Richter Vogelius, Ivan
AU - Lassen, Ulrik
PY - 2019
Y1 - 2019
N2 - Background: Selecting patients for early clinical trials is a challenging process and clinicians lack sufficient tools to predict overall survival (OS). Circulating cell-free DNA (cfDNA) has recently been shown to be a promising prognostic biomarker. The aim of this study was to investigate whether baseline cfDNA measurement could improve the prognostic information of the Royal Marsden Hospital (RMH) score. Methods: Solid tumour patients referred for phase I trials were included in the Copenhagen Personalized Oncology (CoPPO) programme. Baseline characteristics were collected prospectively, including the RMH prognostic score, Eastern Cooperative Oncology Group (ECOG) performance status and concentration of cfDNA per millilitre plasma. Cox proportional hazards model was used to assess the prognostic value of baseline variables. Results: Plasma cfDNA concentration was quantifiable in 302 patients out of a total of 419 included in the study period of 2 years and 5 months. The RMH score was confirmed to be associated with OS. Cell-free DNA was shown to be an independent prognostic marker of OS and improved the risk model, including RMH, performance status and age. Furthermore, both plasma cfDNA concentration and RMH score were associated with treatment allocation (p < 0.00001). Conclusion: Our model based on RMH score, age, ECOG performance status and cfDNA improved prediction of OS and constitutes a clinically valuable tool when selecting patients for early clinical trials. An interactive version of the prognostic model is published on https://bit.ly/phase1survival.
AB - Background: Selecting patients for early clinical trials is a challenging process and clinicians lack sufficient tools to predict overall survival (OS). Circulating cell-free DNA (cfDNA) has recently been shown to be a promising prognostic biomarker. The aim of this study was to investigate whether baseline cfDNA measurement could improve the prognostic information of the Royal Marsden Hospital (RMH) score. Methods: Solid tumour patients referred for phase I trials were included in the Copenhagen Personalized Oncology (CoPPO) programme. Baseline characteristics were collected prospectively, including the RMH prognostic score, Eastern Cooperative Oncology Group (ECOG) performance status and concentration of cfDNA per millilitre plasma. Cox proportional hazards model was used to assess the prognostic value of baseline variables. Results: Plasma cfDNA concentration was quantifiable in 302 patients out of a total of 419 included in the study period of 2 years and 5 months. The RMH score was confirmed to be associated with OS. Cell-free DNA was shown to be an independent prognostic marker of OS and improved the risk model, including RMH, performance status and age. Furthermore, both plasma cfDNA concentration and RMH score were associated with treatment allocation (p < 0.00001). Conclusion: Our model based on RMH score, age, ECOG performance status and cfDNA improved prediction of OS and constitutes a clinically valuable tool when selecting patients for early clinical trials. An interactive version of the prognostic model is published on https://bit.ly/phase1survival.
U2 - 10.1038/s41416-019-0491-9
DO - 10.1038/s41416-019-0491-9
M3 - Journal article
C2 - 31186525
AN - SCOPUS:85067287153
VL - 121
SP - 125
EP - 130
JO - The British journal of cancer. Supplement
JF - The British journal of cancer. Supplement
SN - 0007-0920
IS - 2
ER -
ID: 240631116